Rheumatoid Arthritis
Conditions
Brief summary
This 4 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of P38 Inhibitor (4) (50, 150 or 300mg po qd) monotherapy versus methotrexate monotherapy in adult patients with active rheumatoid arthritis. Patients will be randomized to receive one of 3 doses of P38 Inhibitor (4) or methotrexate. The anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.
Interventions
DRUGP38 Inhibitor (4)
50mg po qd
DRUGPlacebo
po qd
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adult patients \>18 years of age, with active RA; * receiving treatment for RA on an outpatient basis; * females of child-bearing potential, or nonsterilized males with partners of child-bearing potential, must use reliable contraception during, and for 4 weeks after, the study.
Exclusion criteria
* major surgery within 8 weeks prior to screening; * rheumatic autoimmune disease or inflammatory joint disease other than RA; * treatment with methotrexate within 8 weeks of baseline; * concurrent use of DMARDs, including anti-TNF or other biologic therapy for RA.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with ACR 20 response | Week 12 |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of patients with ACR 50/70 response. | Week 12 |
| Change in ACR core set, DAS 28, FACIT-F fatigue assessment, AEs, laboratory parameters. | Throughout study |
Countries
Canada, Croatia, Czechia, France, Italy, Mexico, Romania, Serbia, South Africa, Spain, Taiwan, United States
Outcome results
None listed